Research Article
HLA-G Dimers in the Prolongation of Kidney Allograft Survival
Table 1
Demographic, clinical, therapeutic, and transplant-related parameters of the patients.
| | | NR | CR |
| | Total, n | 50 | 17 | | Gender, n | | | | Male | 14 | 4 | | Female | 36 | 13 | | Recipient age, yr, mean (range) | 51.28 (24–75) | 47.94 (27–75) | | Race, % (n) | | | | Caucasian | 26% (13) | 29.4% (5) | | African American | 70% (35) | 64.7% (11) | | Hispanic | 4% (2) | 5.9% (1) | | Primary cause of renal failure, n | | | | Diabetic nephropathy | 15 | 3 | | Lupus nephritis | — | 3 | | Renal cystic disease | 6 | 1 | | Glomerulosclerosis | 5 | 1 | | Hypertension | 11 | 3 | | Hypertensive kidney disease | 3 | 2 | | Other | 14 | 4 | | Donor type, % (n) | | | | Deceased | 80% (40) | 70.6% (12) | | Living | 20% (10) | 29.4% (5) | | Cold ischemia time, hr, mean ± SD | 16.00 ± 10.01 (n = 45) | 14.57 ± 0.39 (n = 13) | | Creatinine level, mg/dL, mean (range) | 1.48 (0.79–2.56) | 2.71 (1.04–6.46) | | (HLA-A, B, DRB1) matches, mean ± SD | 1.83 ± 0.71 (n = 36) | 2.08 ± 0.66 (n = 13) | | (HLA-A, B, DRB1) mismatches, mean ± SD | 1.42 ± 0.71 (n = 36) | 3.62 ± 0.70 (n = 13) | | Immunosuppressive treatment, n | | | | Azathioprine | 2 | — | | Cyclosporine | 5 | 4 | | Mycophenolate | 30 | 14 | | Prednisone | 34 | 13 | | Rapamycin (Sirolimus) | 5 | 3 | | Tacrolimus | 36 | 9 |
|
|
NR: no rejection; CR: chronic rejection.
|
